Exact Imaging has raised US$10m to accelerate global sales of ExactVu, its micro-ultrasound prostate biopsy system.
The funds will be used to speed up sales and wider adoption of ExactVu worldwide.
ExactVu uses high-resolution micro-ultrasound for urologic imaging. Micro-ultrasound provides higher-resolution images than standard ultrasound, helping clinicians see tissue in greater detail.
The company was co-founded by Sam Ifergan, founder of iGan Partners, and Randy AuCoin, Exact Imaging’s current chief executive.
iGan has supported Exact Imaging across company formation, intellectual property licensing, clinical development, initial commercialisation and all financing rounds to date.
Ifergan said: “Randy and I have worked together for many years, including in a prior medtech company, and it has been a privilege to support him and the Exact Imaging team as we build a truly game-changing company in healthcare.”
The results were featured in the “Game Changer” session at the European Association of Urology Congress in Madrid.
Exact Imaging also expanded its commercial operations in 2025, including launching a dedicated North American salesforce and signing distribution partners across Europe, Japan, South Korea, Taiwan, Brazil, Mexico and additional international markets.
The company said this drove record system sales in 2025 and positions it to continue doubling sales in 2026.
Mr AuCoin said: “This financing is a major milestone for Exact Imaging.
“With the strength of our clinical evidence and growing global demand, this capital allows us to scale our commercial footprint worldwide and bring ExactVu to many more urologists and patients.
In 2025, iGan published its OPTIMUM study in JAMA, which found ExactVu micro-ultrasound was non-inferior to MRI-fusion biopsy for prostate cancer detection in biopsy-naïve men, meaning men who have not previously had a prostate biopsy.
